Interleukin-33 Involvement in Nonsmall Cell Lung Carcinomas: An Update
Abstract
:1. Introduction
2. Interleukin-33 in Lung Cancer
2.1. Serum Interleukin-33 in Lung Cancer Patients
2.2. Evidence of Interleukin-33 in Lung Tumor Cells
3. Interleukin-33 Paradox
4. Interleukin-33 Multiple Pathways
5. Concluding Remarks
Author Contributions
Funding
Conflicts of Interest
References
- Wang, C.; Chen, Z.; Bu, X.; Han, Y.; Shan, S.; Ren, T.; Song, W. IL-33 signaling fuels outgrowth and metastasis of human lung cancer. Biochem. Biophys. Res. Commun. 2016, 479, 461–468. [Google Scholar] [CrossRef]
- Wang, K.; Shan, S.; Yang, Z.; Gu, X.; Wang, Y.; Wang, C.; Ren, T. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model. Oncotarget 2017, 8, 68571–68582. [Google Scholar] [CrossRef] [Green Version]
- Ryan, C.; Burke, L. Pathology of lung tumors. Surgery 2017, 35, 234–242. [Google Scholar]
- Travis, W.D.; Brambilla, E.; Noguchi, M.; Nicholson, A.G.; Geisinger, K.; Yatabe, Y.; Ishikawa, Y.; Wistuba, I.; Flieder, D.B.; Franklin, W. Diagnosis of lung adenocarcinoma in resected specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch. Pathol. Lab. Med. 2012, 137, 685–705. [Google Scholar] [CrossRef]
- Lee, J.M.; Yanagawa, J.; Peebles, K.A.; Sharma, S.; Mao, J.T.; Dubinett, S.M. Inflammation in lung carcinogenesis: New targets for lung cancer chemoprevention and treatment. Crit. Rev. Oncol./Hematol. 2008, 66, 208–217. [Google Scholar] [CrossRef] [Green Version]
- Jurišić, V.; Obradovic, J.; Pavlović, S.; Djordjevic, N. Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Anal. Cell. Pathol. 2018, 2018, 6192187. [Google Scholar] [CrossRef]
- Di Salvo, E.; Ventura-Spagnolo, E.; Casciaro, M.; Navarra, M.; Gangemi, S. IL-33/IL-31 Axis: A Potential Inflammatory Pathway. Mediat. Inflamm. 2018, 2018, 3858032. [Google Scholar] [CrossRef]
- Yang, M.; Feng, Y.; Yue, C.; Xu, B.; Chen, L.; Jiang, J.; Lu, B.; Zhu, Y. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS ONE 2018, 13, e0193428. [Google Scholar] [CrossRef]
- Bonanno, A.; Gangemi, S.; La Grutta, S.; Malizia, V.; Riccobono, L.; Colombo, P.; Cibella, F.; Profita, M. 25-Hydroxyvitamin D, IL-31, and IL-33 in children with allergic disease of the airways. Mediat. Inflamm. 2014, 2014, 520241. [Google Scholar] [CrossRef]
- Vocca, L.; Di Sano, C.; Uasuf, C.G.; Sala, A.; Riccobono, L.; Gangemi, S.; Albano, G.D.; Bonanno, A.; Gagliardo, R.; Profita, M. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology 2015, 220, 954–963. [Google Scholar] [CrossRef]
- Larsen, K.M.; Minaya, M.K.; Vaish, V.; Pena, M.M.O. The Role of IL-33/ST2 Pathway in Tumorigenesis. Int. J. Mol. Sci. 2018, 19. [Google Scholar] [CrossRef]
- Yang, Z.; Gao, X.; Wang, J.; Xu, L.; Zheng, Y.; Xu, Y. Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells. OncoTarg. Ther. 2018, 11, 843. [Google Scholar] [CrossRef]
- Naumnik, W.; Naumnik, B.; Niewiarowska, K.; Ossolinska, M.; Chyczewska, E. Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Exp. Oncol. 2012, 34, 348–353. [Google Scholar]
- Hu, L.A.; Fu, Y.; Zhang, D.N.; Zhang, J. Serum IL-33 as a diagnostic and prognostic marker in non—small cell lung cancer. Asian Pac. J. Cancer Prev. APJCP 2013, 14, 2563–2566. [Google Scholar] [CrossRef]
- Kim, M.S.; Kim, E.; Heo, J.S.; Bae, D.J.; Lee, J.U.; Lee, T.H.; Lee, H.J.; Chang, H.S.; Park, J.S.; Jang, A.S.; et al. Circulating IL-33 level is associated with the progression of lung cancer. Lung Cancer 2015, 90, 346–351. [Google Scholar] [CrossRef]
- Akimoto, M.; Hayashi, J.I.; Nakae, S.; Saito, H.; Takenaga, K. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumor microenvironment of lung cancer. Cell Death Dis. 2016, 7, e2057. [Google Scholar] [CrossRef]
- Sun, M.; Bai, Y.; Zhao, S.; Liu, X.; Gao, Y.; Wang, L.; Liu, B.; Ma, D.; Ma, C. Gram-negative bacteria facilitate tumor progression through TLR4/IL-33 pathway in patients with non-small-cell lung cancer. Oncotarget 2018, 9, 13462–13473. [Google Scholar] [CrossRef] [Green Version]
- Saranchova, I.; Han, J.; Zaman, R.; Arora, H.; Huang, H.; Fenninger, F.; Choi, K.B.; Munro, L.; Pfeifer, C.G.; Welch, I.; et al. Type 2 Innate Lymphocytes Actuate Immunity Against Tumors and Limit Cancer Metastasis. Sci. Rep. 2018, 8, 2924. [Google Scholar] [CrossRef]
- Cui, G.; Qi, H.; Gundersen, M.D.; Yang, H.; Christiansen, I.; Sorbye, S.W.; Goll, R.; Florholmen, J. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol. Immunother. CII 2015, 64, 181–190. [Google Scholar] [CrossRef]
- Tong, X.; Barbour, M.; Hou, K.; Gao, C.; Cao, S.; Zheng, J.; Zhao, Y.; Mu, R.; Jiang, H.-R. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol. Oncol. 2016, 10, 113–125. [Google Scholar] [CrossRef]
- Kim, Y.-W.; West, X.Z.; Byzova, T.V. Inflammation and oxidative stress in angiogenesis and vascular disease. J. Mol. Med. 2013, 91, 323–328. [Google Scholar] [CrossRef] [Green Version]
- Küchler, A.M.; Pollheimer, J.; Balogh, J.; Sponheim, J.; Manley, L.; Sorensen, D.R.; De Angelis, P.M.; Scott, H.; Haraldsen, G. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am. J. Pathol. 2008, 173, 1229–1242. [Google Scholar] [CrossRef]
- Srivastava, S.; Salim, N.; Robertson, M. Interleukin-18: Biology and role in the immunotherapy of cancer. Curr. Med. Chem. 2010, 17, 3353–3357. [Google Scholar] [CrossRef]
- Schmitz, J.; Owyang, A.; Oldham, E.; Song, Y.; Murphy, E.; McClanahan, T.K.; Zurawski, G.; Moshrefi, M.; Qin, J.; Li, X.; et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23, 479–490. [Google Scholar] [CrossRef]
- Imbalzano, E.; Quartuccio, S.; Di Salvo, E.; Crea, T.; Casciaro, M.; Gangemi, S. Association between HMGB1 and asthma: A literature review. Clin. Mol. Allergy 2017, 15, 12. [Google Scholar] [CrossRef]
- Bonilla, W.V.; Fröhlich, A.; Senn, K.; Kallert, S.; Fernandez, M.; Johnson, S.; Kreutzfeldt, M.; Hegazy, A.N.; Schrick, C.; Fallon, P.G. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 2012, 335, 984–989. [Google Scholar] [CrossRef]
- Milovanovic, M.; Volarevic, V.; Radosavljevic, G.; Jovanovic, I.; Pejnovic, N.; Arsenijevic, N.; Lukic, M.L. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 2012, 52, 89–99. [Google Scholar] [CrossRef]
- Ito, N.; Nakamura, H.; Tanaka, Y.; Ohgi, S. Lung carcinoma: Analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer: Interdiscip. Int. J. Am. Cancer Soc. 1999, 85, 2359–2367. [Google Scholar] [CrossRef]
- Chansac, B.L.M.; Moretta, A.; Vergnon, I.; Opolon, P.; Lécluse, Y.; Grunenwald, D.; Kubin, M.; Soria, J.-C.; Chouaib, S.; Mami-Chouaib, F. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J. Immunol. 2005, 175, 5790–5798. [Google Scholar] [CrossRef]
- Koyama, K.; Kagamu, H.; Miura, S.; Hiura, T.; Miyabayashi, T.; Itoh, R.; Kuriyama, H.; Tanaka, H.; Tanaka, J.; Yoshizawa, H. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin. Cancer Res. 2008, 14, 6770–6779. [Google Scholar] [CrossRef]
- Ganesan, A.-P.; Johansson, M.; Ruffell, B.; Beltran, A.; Lau, J.; Jablons, D.M.; Coussens, L.M. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J. Immunol. 2013, 191, 2009–2017. [Google Scholar] [CrossRef] [PubMed]
- Dominguez, D.; Ye, C.; Geng, Z.; Chen, S.; Fan, J.; Qin, L.; Long, A.; Wang, L.; Zhang, Z.; Zhang, Y.; et al. Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J. Immunol. 2017, 198, 1365–1375. [Google Scholar] [CrossRef]
- Jovanovic, I.P.; Pejnovic, N.N.; Radosavljevic, G.D.; Arsenijevic, N.N.; Lukic, M.L. IL-33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunology 2012, 1, 229–231. [Google Scholar] [CrossRef] [Green Version]
- Yu, X.X.; Hu, Z.; Shen, X.; Dong, L.Y.; Zhou, W.Z.; Hu, W.H. IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway. Dig. Dis. Sci. 2015, 60, 1265–1272. [Google Scholar] [CrossRef]
- Kim, J.; Lim, S.; Kim, G.; Yun, H.; Ahn, S.; Choi, H. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene 2015, 34, 4928. [Google Scholar] [CrossRef]
- Brabcová, E.; Kolesár, L.; Thorburn, E.; Striz, I. Chemokines induced in human respiratory epithelial cells by IL-1 family of cytokines. Fol. Boil. 2014, 60, 180. [Google Scholar]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Casciaro, M.; Cardia, R.; Di Salvo, E.; Tuccari, G.; Ieni, A.; Gangemi, S. Interleukin-33 Involvement in Nonsmall Cell Lung Carcinomas: An Update. Biomolecules 2019, 9, 203. https://doi.org/10.3390/biom9050203
Casciaro M, Cardia R, Di Salvo E, Tuccari G, Ieni A, Gangemi S. Interleukin-33 Involvement in Nonsmall Cell Lung Carcinomas: An Update. Biomolecules. 2019; 9(5):203. https://doi.org/10.3390/biom9050203
Chicago/Turabian StyleCasciaro, Marco, Roberta Cardia, Eleonora Di Salvo, Giovanni Tuccari, Antonio Ieni, and Sebastiano Gangemi. 2019. "Interleukin-33 Involvement in Nonsmall Cell Lung Carcinomas: An Update" Biomolecules 9, no. 5: 203. https://doi.org/10.3390/biom9050203